Follow-up of cognition and cerebral hemodynamics in older adults with normal cognitive function and older adults with Mild Cognitive Impairment

Follow-up of cognition and cerebral hemodynamics in older adults with normal cognitive function and older adults with Mild Cognitive Impairment - Cognition and cerebral hemodynamics in healthy aging and MCI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48116

Enrollment

Registered

2019-11-25

Start date

2020-01-03

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cognitive impairment

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Participated in one of our previous two studies (NL19014.091.07 or NL54544.091.15); - Informed consent; - Adequate visual and auditory acuity to allow neuropsychological testing; - Caregiver/informant available (applicable to cognitively impaired patients).

Exclusion criteria

Exclusion criteria: - Participants currently enrolled in any investigational drug study.

Design outcomes

Primary

Measure	Time frame
The change in cerebrovascular and cognitive function between the post-intervention measurements from the previous studies and the measurements from this follow-up study. Cognitive function will be assessed by comprehensive neuropsychological testing involving the tests listed in the protocol of the study in which each individual participated in (either NL54544.091.15 or NL19014.091.07). Cerebrovascular function measures will consist of cerebral autoregulation and cerebral vasomotor reactivity.	—

Measure

Time frame

The change in cerebrovascular and cognitive function between the post-intervention measurements from the previous studies and the measurements from this follow-up study. Cognitive function will be assessed by comprehensive neuropsychological testing involving the tests listed in the protocol of the study in which each individual participated in (either NL54544.091.15 or NL19014.091.07). Cerebrovascular function measures will consist of cerebral autoregulation and cerebral vasomotor reactivity.

—

Secondary

Measure	Time frame
The (change in) physical fitness will be assessed using a submaximal incremental cycling test, hand grip strength test, 30 second chair stand test, and a physical activity questionnaire (LAPAQ). Other study parameters include clinical data on progression of cognitive impairment (new onset of MCI, changes in severity of MCI, progression to Alzheimer*s disease or dementia) or development of other diseases or comorbid conditions.	—

Measure

Time frame

The (change in) physical fitness will be assessed using a submaximal incremental cycling test, hand grip strength test, 30 second chair stand test, and a physical activity questionnaire (LAPAQ). Other study parameters include clinical data on progression of cognitive impairment (new onset of MCI, changes in severity of MCI, progression to Alzheimer*s disease or dementia) or development of other diseases or comorbid conditions.

—

Countries

Netherlands

Outcome results